AM Desk 01 of 05
Canada, the United States and Latin America: regulators, launches, prices, plants and trade rules for peptide medicines across the hemisphere.
10 stories
BRBrazilMarket
Torrent Pharmaceuticals told investors it expects to launch generic semaglutide in Brazil within six to nine months, after Brazil sales rose 38 percent in the September quarter.
USUnited StatesRules
Treasury proposed on 22 October 2026 to add biotechnology, including biomanufacturing equipment and facilities, to US outbound investment screening under the COINS Act.
USUnited StatesMaking
DuPont launched AmberChrom SIL, a C8 and C18 reverse phase silica gel for peptide purification from crude cleanup to final polishing.
USUnited StatesRules
A factory under construction became a way to avoid a tariff.
USUnited StatesMaking
Not every new GLP-1 needs a peptide factory; the pill is made by ordinary chemical synthesis.
USUnited StatesMaking
The largest US plant plan yet from a GLP-1 maker, announced before the sites were even chosen.
USUnited StatesMaking
More of the step that turns bulk peptide into finished pens moves next to Novo's US customers.
USUnited StatesMoney
Another case of buying a working sterile site rather than building one.
USUnited StatesMaking
The ingredient behind Mounjaro and Zepbound gets a second very large home in Indiana.
USUnited StatesMoney
A mid-sized contract maker bets heavily that drug companies will keep outsourcing peptide chemistry.
